Abstract:Abstract Background Primary biliary cholangitis (PBC) is a chronic autoimmune cholestatic liver disease that can progress to liver fibrosis and cirrhosis, and requires timely diagnosis, optimal treatment, and risk stratification. Several guidelines for the management of PBC have been published, including the American Association for the Study of Liver Disease (AASLD) and European Association for the Study of the Liver (EASL) Clinical Practice Guidelines, which include goals for standards of PBC care. However, recent audits have identified deficiencies in real-world PBC care. In addition, the global coronavirus (COVID-19) pandemic has generally reduced access to care, diminished healthcare resources and accelerated the use of remote patient management. There is therefore a need for simple, actionable guidance that physicians can implement in order to maintain standards of care in PBC in the new environment. Aims A working group of ten PBC specialists from Europe and Canada were convened by Intercept Pharmaceuticals in January 2020 with the aim of defining key criteria for the care of patients with PBC. Methods Following the outbreak of the COVID-19 pandemic, based on these criteria, a smaller working group of six PBC specialists developed practical recommendations to assist physicians in maintaining standards of care and to guide remote management of patients. Results The working group defined five key criteria for care in PBC, encompassing PBC diagnosis, initiation of first line therapy with ursodeoxycholic acid (UDCA), risk stratification on UDCA, symptom management, and initiation of 2L therapy. The group developed 21 practical recommendations for the management of patients with PBC in the COVID-19 environment including modality, frequency and timing of investigations and monitoring. (Figure 1). Conclusions The delivery of PBC care during the COVID-19 pandemic carries significant challenges. These consensus criteria and practical recommendations provide guidance for the management of PBC during the pandemic era and beyond. Funding Agencies NoneIntercept Pharmaceutical

Guidelines on the Diagnosis and Management of Primary Biliary Cholangitis (2021)

Consensus on the Diagnosis and Treatment of Cholestatic Liver Diseases (2015, China)

Guidelines for the Management of Cholestatic Liver Diseases (2021)

Guidelines for the Diagnosis and Treatment of Hepatocellular Carcinoma (2019 Edition).

Primary biliary cholangitis: opportunities and challenges

Application of the Latest Advances in Evidence-Based Medicine in Primary Biliary Cholangitis

Current Status of Diagnosis and Treatment of Primary Biliary Cholangitis and Related Challenges in China

2019 Chinese clinical guidelines for the management of hepatocellular carcinoma: updates and insights

Guidelines for the Diagnosis and Treatment of Pancreatic Cancer in China (2021)

Guideline of Prevention and Treatment for Chronic Hepatitis B (2015 Update)

Guidelines for the Diagnosis and Treatment of Primary Liver Cancer (2022 Edition)

A209 EXPERT CONSENSUS CRITERIA AND PRACTICAL RECOMMENDATIONS FOR PBC CARE IN THE COVID-19 ERA AND BEYOND

Comparison of Current Guidelines and Consensus on the Management of Patients with Cholangiocarcinoma: 2022 Update.

Chinese Clinical Practice Guidelines for the Prevention and Treatment of Mother-to-Child Transmission of Hepatitis B Virus (version 2024)

Guidelines for Diagnosis and Treatment of Primary Liver Cancer in China (2017 Edition)

Diagnosis and Treatment of Primary Biliary Cholangitis: A Patient‐Friendly Summary of the 2018 AASLD Practice Guidance

Clinical Analysis of Primary Biliary Cirrhosis: a Report of 31 Cases

Chinese Guidelines On The Management Of Liver Cirrhosis (Abbreviated Version)

Treatment of primary biliary cirrhosis with ursodeoxycholic acid combined with traditional Chinese medicine A protocol for systematic review and meta analysis

Guidelines for the diagnosis and treatment of chronic pancreatitis in China (2018 edition).

Guidelines for Diagnosis and Treatment of Hepatocellular Carcinoma with Portal Vein Tumor Thrombus in China (2021 Edition)